ClinicalTrials.gg
TerminatedNCT04862143TELEPIKUpdated Jun 20, 2024Results posted

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

A Phase 2 interventional study of Alpelisib and Fulvestrant in Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 1 site in Sweden. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study early terminated due to low enrollment compared to the anticipated figures

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
37th of 38
2 · median 44
Started
2022
with 3 others
Phase 2
15 of 38
2 open now
Registered
27th of 38
by date
Lead sponsor
18 of 38
Novartis Pharmaceuticals

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 37th largest by enrollment, is one of 4 that started in 2022, is one of 15 in phase 2, and was the 27th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

The study was designed to identify and register practical observations and experiences in connection with planning and implementing decentralized, patient-centered clinical trials at a geographic distance with virtual elements.

Read the detailed description

The purpose of this open-label, single arm, multi-center, Phase II interventional pilot trial was to evaluate if a decentralized clinical trial (DCT) using a telemedicine platform offers a satisfactory, safe and suitable management for HR-positive/HER2-negative participants with advanced breast cancer harboring a PIK3CA mutation and treated with alpelisib plus fulvestrant. The trial utilized a hybrid DCT approach to reduce participant burden by bringing visits, services, and supplies closer to them.

The planned duration of treatment was 12 cycles of 28 days. Participants could discontinue treatment earlier due to unacceptable toxicity, disease progression and/or decision made at the discretion of the investigator or the participant.

On-site visits occurred during screening, at Cycle 1 Day 1 (baseline), and at end-of-trial. Visits at the local oncologist practice were planned on Day 1 of Cycle 2, Cycle 4, Cycle 7, and Cycle 10. Other visits were performed by a district nurse, either at home or at the local oncologist's practice, depending on the participant's preference.

During the on-site visit on Cycle 1, Day 1, participants were trained on using the telemedicine platform, and other monitoring devices used during remote participation: a glucometer and a smartphone with the telemedicine application installed. Study treatment was also initiated during this visit. The participants were then transitioned to remote participation enabled by the telemedicine platform with support of local healthcare providers (local oncologist, district nurse, or other qualified healthcare professional) under the investigator's oversight.

Discontinuation of remote participation was not a reason for trial termination. Participants who did not wish to continue with remote participation had the option to attend on-site visits.

The study planned to enroll approximately 20 participants, however the study was terminated prematurely with only 2 participants enrolled. The decision to terminate the study was due to delays during the start-up period and due to low enrollment. The decision to terminate was not related to any potential safety concern with alpelisib.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • Decentralized clinical trial
  • advanced breast cancer
  • PIK3CA mutation
  • alpelisib
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant is an adult ≥18 years old at the time of consent
  2. Participant with ABC (loco regionally recurrent or ) not amenable to curative therapy.
  3. Participant with a and/or cytologically confirmed diagnosis of ER-positive and/or PR-positive breast cancer by local laboratory.
  4. Participant with a confirmed -negative ABC.
  5. Participant with a pathology report confirming PIK3CA mutant status by a certified laboratory using a validated PIK3CA mutation assay (from either tissue or blood).
  6. Participant was willing to operate a smartphone compatible with the software of the medical device and willing to manage applications
  7. Participant was willing to use the telemedicine platform and to follow the remote participant monitoring procedure.

Key Exclusion Criteria:

  1. Participant had received prior treatment with any PI3K, mTOR or AKT inhibitor.
  2. Participant with known to alpelisib or fulvestrant, or to any of the of alpelisib or fulvestrant.
  3. Participant participated in a prior study within 30 days prior to the start of trial treatment or within 5 half-lives of the trial treatment, whichever was longer.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Alpelisib + fulvestrant

    Participants were administered alpelisib at a daily dose of 300 mg for 12 cycles of 28 days and fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and Day 1 of each subsequent cycle up to Cycle 12. Pre-menopausal women also received goserelin at a dose of 3.6 mg on Day 1 of each cycle.

    Drug: Alpelisib · Drug: Fulvestrant · Drug: Goserelin

Interventions

  • Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.

    Also known as: BYL719

  • Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.

  • Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.

06

What researchers measure

Primary outcomes

  1. Participant Satisfaction Assessed Through the Trial Feedback Questionnaire (TFQ)

    The TFQ was designed to capture the patient's experience during a clinical trial. The questionnaire consisted of 23 questions that assessed various aspects of the trial experience. Each question in the TFQ scored on a scale ranging from 1 (representing the worst response) to 5 (representing the best response). To calculate the total score, the scores obtained from each of the 23 questions were summed up. The resulting sum represented the participant's total score, which could ranged from 23 (indicating the lowest possible score) to 115 (indicating the highest possible score).

    Time frame: Baseline, and on Day 1 of Cycle 4 and 7. Cycle= 28 days

Secondary outcomes

  1. Patient Retention on the Decentralized Clinical Trial (DCT) Approach

    Patient retention on the DCT approach was calculated as the percentage of participants on remote monitoring for participants still on treatment

    Time frame: At 3 and 6 months

  2. Number of Unscheduled In-clinic Visits

    Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits was evaluated

    Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months

  3. Number of Unscheduled In-clinic Visits Because of Safety Reasons

    Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits that were prompted by safety reasons was evaluated

    Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months

  4. Number of Unscheduled In-clinic Visits Per Participant in the Study

    Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits per participants was evaluated

    Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months

  5. Number of Participants Who Discontinue Treatment Due to Adverse Events (AEs)

    An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants who discontinued the treatment due to adverse events was evaluated

    Time frame: From the date of the first study treatment up to the end of treatment, assessed up to 6 months

  6. Number of Participants With Dose Reductions/Interruptions for Alpelisib

    Number of participants with dose reductions and interruptions for alpelisib

    Time frame: From the date of the first study treatment up to the end of treatment, assessed up to 6 months

  7. Number of Participants With Adverse Events of Special Interest (AESIs)- Hyperglycemia, Rash and Diarrhea

    AESIs (Adverse Events of Special Interest) are defined as events, whether serious or non-serious, that are of scientific and medical concern specific to the sponsor's product or program. These events may require ongoing monitoring and communication by the investigator to the sponsor. For this study, the following AESIs were defined: hyperglycemia, rash, and diarrhea. The number of participants experiencing these events per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 was evaluated.

    Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months

  8. Number of Participants With Adverse Events (AEs) Leading to In-clinic Visits

    An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants with AEs per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 leading to in-clinic visits was assessed.

    Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months

  9. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 questionnaire contained 30 items and was composed of both multi-item scales and single item measures. These included five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/quality of life (QoL) scale. All of the scales and single items ranged from 0 to 100. A high scale score represented a higher response level. Thus, a high score for a functional scale indicated a high/healthy level of functioning, a high score for the QoL indicated high QoL, but a high score for a symptom scale/single item indicated a high level of symptomatology/problems. The EORTC QLQ-C30 scores for all functional and symptom scales were evaluated

    Time frame: Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days

  10. EuroQol 5-Dimension 5-Level (EQ-5D-5L)- Visual Analog Scale (VAS) Score

    The 5-level EQ-5D (EQ-5D-5L) questionnaire is a standardized measure of health status. The EQ-5D descriptive system comprises of the 5 following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Along with the five dimensions of health, the EQ-5D-5L includes a VAS where respondents rate their overall health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The EQ-5D-5L VAS scores were evaluated

    Time frame: Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days

  11. Brief Pain Inventory Short Form (BPI-SF) Scores

    The BPI-SF was a questionnaire used to assess pain intensity and interference with daily activities. The Pain Severity Subscale included four questions asking individuals to rate their pain intensity on a scale from 0 to 10, with higher scores indicating more severe pain. The Pain Interference Subscale consisted of seven items that assessed how pain had interfered with activities, rated on the same scale. Both subscales had a total score range of 0 to 10, with higher scores indicating more significant pain or interference.

    Time frame: Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days

  12. Number of Participants With Progression-free Survival (PFS) According to RECIST 1.1

    The number of participants with PFS was defined as the count of participants who did not experience disease progression or death due to any cause during the study. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on local radiology review.

    Time frame: Up to 6 months

07

Results

Posted Feb 20, 2024

Participant flow

The study was conducted in 1 center from Sweden

Participant flow — Overall Study
MilestoneAlpelisib + Fulvestrant
Started2
Completed0
Not completed2
Withdrew: Adverse event1
Withdrew: Study terminated by sponsor1

Outcome measures

PrimaryParticipant Satisfaction Assessed Through the Trial Feedback Questionnaire (TFQ)

The TFQ was designed to capture the patient's experience during a clinical trial. The questionnaire consisted of 23 questions that assessed various aspects of the trial experience. Each question in the TFQ scored on a scale ranging from 1 (representing the worst response) to 5 (representing the best response). To calculate the total score, the scores obtained from each of the 23 questions were summed up. The resulting sum represented the participant's total score, which could ranged from 23 (indicating the lowest possible score) to 115 (indicating the highest possible score).

Time frame:
Baseline, and on Day 1 of Cycle 4 and 7. Cycle= 28 days
Reported as:
Median · Score on a Scale
Participant Satisfaction Assessed Through the Trial Feedback Questionnaire (TFQ)
Score on a ScaleAlpelisib + Fulvestrant
Baseline99.5 (92 to 107)
Cycle 4 Day 189
Cycle 7 Day 198
SecondaryPatient Retention on the Decentralized Clinical Trial (DCT) Approach

Patient retention on the DCT approach was calculated as the percentage of participants on remote monitoring for participants still on treatment

Time frame:
At 3 and 6 months
Reported as:
Count of participants · Participants
Patient Retention on the Decentralized Clinical Trial (DCT) Approach
ParticipantsAlpelisib + Fulvestrant
3 months1
6 months1
SecondaryNumber of Unscheduled In-clinic Visits

Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits was evaluated

Time frame:
From the date of the first study treatment up to the end of study, assessed up to 6 months
Reported as:
Number · Visits
Number of Unscheduled In-clinic Visits
VisitsAlpelisib + Fulvestrant
Number of Unscheduled In-clinic Visits0
SecondaryNumber of Unscheduled In-clinic Visits Because of Safety Reasons

Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits that were prompted by safety reasons was evaluated

Time frame:
From the date of the first study treatment up to the end of study, assessed up to 6 months
Reported as:
Median · Visits
Number of Unscheduled In-clinic Visits Because of Safety Reasons
VisitsAlpelisib + Fulvestrant
Number of Unscheduled In-clinic Visits Because of Safety Reasons0 (0 to 0)
SecondaryNumber of Unscheduled In-clinic Visits Per Participant in the Study

Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits per participants was evaluated

Time frame:
From the date of the first study treatment up to the end of study, assessed up to 6 months
Reported as:
Median · Visits per participant
Number of Unscheduled In-clinic Visits Per Participant in the Study
Visits per participantAlpelisib + Fulvestrant
Number of Unscheduled In-clinic Visits Per Participant in the Study0 (0 to 0)
SecondaryNumber of Participants Who Discontinue Treatment Due to Adverse Events (AEs)

An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants who discontinued the treatment due to adverse events was evaluated

Time frame:
From the date of the first study treatment up to the end of treatment, assessed up to 6 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to Adverse Events (AEs)
ParticipantsAlpelisib + Fulvestrant
Number of Participants Who Discontinue Treatment Due to Adverse Events (AEs)1
SecondaryNumber of Participants With Dose Reductions/Interruptions for Alpelisib

Number of participants with dose reductions and interruptions for alpelisib

Time frame:
From the date of the first study treatment up to the end of treatment, assessed up to 6 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Reductions/Interruptions for Alpelisib
ParticipantsAlpelisib + Fulvestrant
Dose interruptions1
Dose reductions1
SecondaryNumber of Participants With Adverse Events of Special Interest (AESIs)- Hyperglycemia, Rash and Diarrhea

AESIs (Adverse Events of Special Interest) are defined as events, whether serious or non-serious, that are of scientific and medical concern specific to the sponsor's product or program. These events may require ongoing monitoring and communication by the investigator to the sponsor. For this study, the following AESIs were defined: hyperglycemia, rash, and diarrhea. The number of participants experiencing these events per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 was evaluated.

Time frame:
From the date of the first study treatment up to the end of study, assessed up to 6 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)- Hyperglycemia, Rash and Diarrhea
ParticipantsAlpelisib + Fulvestrant
Diarrhea1
Hyperglycaemia2
Rash0
SecondaryNumber of Participants With Adverse Events (AEs) Leading to In-clinic Visits

An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants with AEs per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 leading to in-clinic visits was assessed.

Time frame:
From the date of the first study treatment up to the end of study, assessed up to 6 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Leading to In-clinic Visits
ParticipantsAlpelisib + Fulvestrant
Number of Participants With Adverse Events (AEs) Leading to In-clinic Visits0
SecondaryEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

The EORTC QLQ-C30 questionnaire contained 30 items and was composed of both multi-item scales and single item measures. These included five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/quality of life (QoL) scale. All of the scales and single items ranged from 0 to 100. A high scale score represented a higher response level. Thus, a high score for a functional scale indicated a high/healthy level of functioning, a high score for the QoL indicated high QoL, but a high score for a symptom scale/single item indicated a high level of symptomatology/problems. The EORTC QLQ-C30 scores for all functional and symptom scales were evaluated

Time frame:
Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days
Reported as:
Median · Score on a Scale
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Score on a ScaleAlpelisib + Fulvestrant
QoL- Baseline75 (67 to 83)
QoL- Cycle 4 Day 183
QoL- Cycle 7 Day 192
QoL- End of Treatment75 (67 to 83)
Physical Functioning- Baseline90 (80 to 100)
Physical Functioning- Cycle 4 Day 193
Physical Functioning- Cycle 7 Day 1100
Physical Functioning-End of Treatment86.5 (80 to 93)
Role Functioning- Baseline91.5 (83 to 100)
Role Functioning- Cycle 4 Day 1100
Role Functioning- Cycle 7 Day 1100
Role Functioning-End of Treatment83.5 (67 to 100)
Emotional Functioning- Baseline71 (67 to 75)
Emotional Functioning- Cycle 4 Day 183
Emotional Functioning- Cycle 7 Day 192
Emotional Functioning- End of treatment83 (83 to 83)
Cognitive Functioning- Baseline91.5 (83 to 100)
Cognitive Functioning- Cycle 4 Day 1100
Cognitive Functioning- Cycle 7 Day 1100
Cognitive Functioning- End of treatment75 (67 to 83)
Social Functioning- Baseline91.5 (83 to 100)
Social Functioning- Cycle 4 Day 1100
Social Functioning- Cycle 7 Day 1100
Social Functioning- End of treatment91.5 (83 to 100)
Fatigue- Baseline22 (0 to 44)
Fatigue- Cycle 4 Day 122
Fatigue- Cycle 7 Day 10
Fatigue- End of treatment33 (22 to 44)
Nausea/vomiting- Baseline0 (0 to 0)
Nausea/vomiting- Cycle 4 Day 117
Nausea/vomiting- Cycle 7 Day 10
Nausea/vomiting- End of treatment0 (0 to 0)
Pain- Baseline8.5 (0 to 17)
Pain- Cycle 4 Day 10
Pain- Cycle 7 Day 10
Pain- End of treatment16.5 (0 to 33)
SecondaryEuroQol 5-Dimension 5-Level (EQ-5D-5L)- Visual Analog Scale (VAS) Score

The 5-level EQ-5D (EQ-5D-5L) questionnaire is a standardized measure of health status. The EQ-5D descriptive system comprises of the 5 following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Along with the five dimensions of health, the EQ-5D-5L includes a VAS where respondents rate their overall health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The EQ-5D-5L VAS scores were evaluated

Time frame:
Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days
Reported as:
Median · Score on a scale
EuroQol 5-Dimension 5-Level (EQ-5D-5L)- Visual Analog Scale (VAS) Score
Score on a scaleAlpelisib + Fulvestrant
Baseline80 (75 to 85)
Cycle 4 Day 193
Cycle 7 Day 195
End of treatment82.5 (70 to 95)
SecondaryBrief Pain Inventory Short Form (BPI-SF) Scores

The BPI-SF was a questionnaire used to assess pain intensity and interference with daily activities. The Pain Severity Subscale included four questions asking individuals to rate their pain intensity on a scale from 0 to 10, with higher scores indicating more severe pain. The Pain Interference Subscale consisted of seven items that assessed how pain had interfered with activities, rated on the same scale. Both subscales had a total score range of 0 to 10, with higher scores indicating more significant pain or interference.

Time frame:
Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days
Reported as:
Median · Score on a scale
Brief Pain Inventory Short Form (BPI-SF) Scores
Score on a scaleAlpelisib + Fulvestrant
Pain severity- Baseline1.63 (1.25 to 2.00)
Pain severity- Cycle 4 Day 10
Pain severity- Cycle 7 Day 10.75
Pain severity- End of treatment1.13 (0.00 to 2.25)
Pain interference- Baseline0.79 (0.00 to 1.57)
Pain interference- Cycle 4 Day 10
Pain interference- Cycle 7 Day 10
Pain interference- End of treatment1.07 (0 to 2.14)
SecondaryNumber of Participants With Progression-free Survival (PFS) According to RECIST 1.1

The number of participants with PFS was defined as the count of participants who did not experience disease progression or death due to any cause during the study. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on local radiology review.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Number of Participants With Progression-free Survival (PFS) According to RECIST 1.1
ParticipantsAlpelisib + Fulvestrant
Number of Participants With Progression-free Survival (PFS) According to RECIST 1.12

Adverse events

Collected over From start up to end of study, assessed up to 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpelisib + Fulvestrant0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAlpelisib + Fulvestrant
HyperglycaemiaMetabolism and nutrition disorders2/2
FatigueGeneral disorders2/2
NauseaGastrointestinal disorders2/2
Abdominal painGastrointestinal disorders1/2
AlopeciaSkin and subcutaneous tissue disorders1/2
Decreased appetiteMetabolism and nutrition disorders1/2
DiarrheaGastrointestinal disorders1/2
Dry mouthGastrointestinal disorders1/2
GastritisGastrointestinal disorders1/2
StomatitisGastrointestinal disorders1/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Alpelisib + Fulvestrant
Mean54 ± 0
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Alpelisib + Fulvestrant
Unknown2
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Alpelisib + Fulvestrant
08

Study locations

1 site
  • Novartis Investigative Site
    Orebro, 701 85, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Sep 2022, 6 months.

Results were first posted in Feb 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 27, 2021
StartActual
Mar 8, 2022
Primary completionActual
Sep 19, 2022
CompletionActual
Sep 19, 2022
Results first posted
Feb 20, 2024
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04862143
Responsible party
Sponsor
First posted
Apr 27, 2021
Start date
Mar 8, 2022
Primary completion
Sep 19, 2022
Completion
Sep 19, 2022
Results posted
Feb 20, 2024
Last update
Jun 20, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion